# US 2022/0041548 A1 · Compounds and compositions comprising the same for treating hypertension or heart failure

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0041548 A1
- Document ID: US20220041548A1
- Status: Published application
- Kind: A1
- Application number: 17/437,862
- Filed: 2020-03-11
- Published: 2022-02-10
- Earliest claimed: 2019-03-11
- Assignees: Quantum Genomics; Institut National de la Sante et de la Recherche Medicale; Centre National De La Recherche Scientifique; College De France
- Applicants: Quantum Genomics; Institut National De La Sante Et De La Recherche Medicale; Centre National De La Recherche Scientifique; College De France
- Inventors: FABRICE BALAVOINE; DELPHINE COMPERE; MATHILDE KECK; YANNICK MARC; CATHERINE LLORENS-CORTES; SOLÈNE E. BOITARD
- Web page: https://patentgrep.com/patent/US20220041548A1

## CPC

- A61K 33/04: Sulfur, selenium or tellurium; Compounds thereof
- C07C 323/58: with amino groups bound to the carbon skeleton
- A61K 31/10: Sulfides; Sulfoxides; Sulfones
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 33/42: Phosphorus; Compounds thereof
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 13/12: of the kidneys
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/06: Antiglaucoma agents or miotics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds, to compositions comprising the same, to methods for preparing the compounds, and the use of these compounds in therapy. In particular, the present invention relates to a compound that is useful in the treatment and prevention of primary and secondary arterial hypertension, ictus, myocardial ischaemia, cardiac and renal insufficiency, myocardial infarction, peripheral vascular disease, diabetic proteinuria, Syndrome X and glaucoma.

## Claims

### Claim at position 1

1-11. (canceled)

### Claim 12

A compound having the following formula (I):
or formula (II):
Wherein:
AH represents —CO2H, —SO3H, —PO3H2;
m is 1, 2 or 3;
R1 and R2 represent independently H, a C1-6 alkyl, C2-6 alkenyl or C2-6 alkynyl group, each alkyl, alkenyl or alkynyl group being optionally substituted by at least one of the following radicals selected from aryl, heterocycle, cycloalkyl, O-aryl, O-arylalkyl or O-cycloalkyl group; said aryl, heterocycle, cycloalkyl, O-aryl, O-arylalkyl, O-cycloalkyl group being optionally substituted with one or more radicals selected from a halogen atom, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, an acyl group, an O-cycloalkyl group, a heteroalkyl group, an O-aryl group, an O-arylalkyl group, an aryl group, a heterocycle group or an arylalkyl group;
a pharmaceutical salt, solvate, zwitterionic form or any prodrug thereof.

### Claim 13 (depends on 12)

The compound according to claim 12, wherein R1 and R2 represent independently H or a C1-6 alkyl, each alkyl group being optionally substituted by at least one of the following radicals selected from aryl, heterocycle or cycloalkyl group; said aryl, heterocycle, cycloalkyl group being optionally substituted with one or more radicals selected from a halogen atom, an alkyl group, an alkoxy group, a haloalkyl group, a haloalkoxy group, an acyl group, an O-cycloalkyl group, a heteroalkyl group, an O-aryl group, an O-arylalkyl group, an aryl group, a heterocycle group or an arylalkyl group.

### Claim 14 (depends on 12)

The compound according to claim 12, wherein R1 and R2 are both H, or, alternatively, R1 is H and R2 is a benzyl or phenethyl group.

### Claim 15 (depends on 12)

The compound according to claim 12, wherein the compound corresponds to general formula (I) and more specifically formula (II), wherein one, two, three or four of the following features are fulfilled:
m is 2 or 3; and/or
AH is CO2H or SO3H; and/or
R1 is H; and/or
R2 is H or an alkyl, preferably an alkyl substituted by a phenyl group.

### Claim 16 (depends on 12)

The compound according to claim 12, wherein the compound corresponds to general formula (I) or formula (II), wherein one, two or three of the following features are fulfilled:
m is 2; and/or
AH is SO3H; and/or
R1 and R2 are both H, or, alternatively, R1 is H and R2 is a phenethyl group.

### Claim 17 (depends on 12)

The compound according to claim 12, which is selected from the group consisting of:
(2R)-2-amino-3-{[(2S)-2-amino-4-sulfobutyl]disulfanyl}propanoic acid,
(2R)-2-amino-3-{[(3S,4S)-4-amino-1-phenyl-6-sulfohexan-3-yl]disulfanyl}propanoic acid, and a pharmaceutical salt, solvate, zwitterionic form or any prodrug thereof.

### Claim 18 (depends on 12)

A pharmaceutical composition comprising at least one compound as defined in claim 12 and a pharmaceutically acceptable carrier.

### Claim at position 9

19-21. (canceled)

### Claim 22 (depends on 18)

The pharmaceutical composition according to claim 18, wherein said compound is selected from the group consisting of:
(2R)-2-amino-3-{[(2S)-2-amino-4-sulfobutyl]disulfanyl}propanoic acid,
a pharmaceutical salt, solvate, zwitterionic form or any prodrug thereof.

### Claim 23 (depends on 18)

The pharmaceutical composition according to claim 18, wherein said compound has the following formula (I):
or formula (II):
wherein:
m is 2;
AH is SO3H; and
R1 and R2 are both H, or, alternatively, R1 is H and R2 is a phenethyl group.

### Claim 24 (depends on 18)

The pharmaceutical composition according to claim 18, wherein said compound has the following formula (I):
or formula (II):
wherein:
m is 2 or 3;
AH is CO2H or SO3H;
R is H; and
R2 is H, an alkyl, or an alkyl substituted by a phenyl group.

### Claim 25 (depends on 18)

The pharmaceutical composition according to claim 18, wherein said compound has the following formula (I):
or formula (II):
wherein:
AH represents —CO2H, —SO3H, —PO3H2;
m is 1, 2 or 3; and
R1 and R2 are both H, or, alternatively, R1 is H and R2 is a benzyl or phenethyl group.

### Claim 26 (depends on 12)

A method for prevention or treatment of arterial hypertension and indirectly and directly related diseases, comprising administration of a therapeutically effective amount of a compound according to claim 12.

### Claim 27 (depends on 26)

The method according to claim 26, wherein said disorders directly or indirectly related to arterial hypertension are selected in the group consisting of heart disease, heart failure, stroke, peripheral and/or cerebral vascular system diseases, brain, eye and/or kidney diseases.

### Claim 28 (depends on 26)

The method according to claim 26, wherein said disorders are selected in the group consisting of primary and/or secondary arterial hypertension, an ictus, myocardial ischemia, cardiac insufficiency, renal insufficiency, myocardial infarction, a peripheral vascular disease, diabetic proteinuria, syndrome X, glaucoma, neurodegenerative diseases and memory disorders.

### Claim 29 (depends on 26)

The method according to claim 26, wherein said compound is selected from the group consisting of:
(2R)-2-amino-3-{[(2S)-2-amino-4-sulfobutyl]disulfanyl}propanoic acid,
(2R)-2-amino-3-{[(3S,4S)-4-amino-1-phenyl-6-sulfohexan-3-yl]disulfanyl}propanoic acid, and a pharmaceutical salt, solvate, zwitterionic form or any prodrug thereof.

### Claim 30 (depends on 26)

The method according to claim 26, wherein said compound has the following formula (I):
or formula (II):
wherein:
m is 2;
AH is SO3H; and
R1 and R2 are both H, or, alternatively, R1 is H and R, is a phenethyl group.

### Claim 31 (depends on 26)

The method according to claim 26, wherein said compound has the following formula (I):
or formula (II):
wherein:
m is 2 or 3;
AH is CO2H or SO3H;
R1 is H; and
R2 is H, an alkyl, or an alkyl substituted by a phenyl group.

### Claim 32 (depends on 26)

The method according to claim 26, wherein said compound has the following formula (I):
or formula (II):
wherein:
AH represents —CO2H, —SO3H, —PO3H2;
m is 1, 2 or 3; and
R1 and R2 are both H, or, alternatively, R1 is H and R2 is a benzyl or phenethyl group.
